MRVI - Maravai LifeSciences Holdings Inc Stock Price, Fair Value and News

11.37USD+0.27 (+2.43%)Delayed as of 17 May 2024, 01:02 pm ET

Market Summary

USD11.37+0.27

Delayedas of 17 May 2024, 01:02 pm

2.43%

MRVI Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

MRVI Stock Price

View Fullscreen

MRVI RSI Chart

MRVI Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-11.21

Price/Sales (Trailing)

5.36

EV/EBITDA

2.17

Price/Free Cashflow

-47.9

MRVI Price/Sales (Trailing)

MRVI Profitability

Operating Margin

44.03%

EBT Margin

218.84%

Return on Equity

-16.86%

Return on Assets

-9.07%

Free Cashflow Yield

-2.09%

MRVI Fundamentals

MRVI Revenue

Revenue (TTM)

274.1M

Rev. Growth (Yr)

-18.79%

Rev. Growth (Qtr)

-13.44%

MRVI Earnings

Earnings (TTM)

-131.0M

Earnings Growth (Yr)

-17.9K%

Earnings Growth (Qtr)

88.6%

Breaking Down MRVI Revenue

52 Week Range

9.0914.88

(Low)(High)

Last 7 days

12.6%

Last 30 days

36.4%

Last 90 days

109.0%

Trailing 12 Months

-13.4%

How does MRVI drawdown profile look like?

MRVI Financial Health

Current Ratio

11.32

Debt/Equity

0.67

Debt/Cashflow

0.06

MRVI Investor Care

Shares Dilution (1Y)

0.45%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	274.1M	0	0	0
2023	717.7M	543.9M	419.5M	288.9M
2022	895.3M	920.3M	906.7M	883.0M
2021	381.3M	552.2M	669.1M	799.2M
2020	178.4M	213.6M	248.9M	284.1M
2019	0	0	0	143.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Maravai LifeSciences Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	oreshack kurt	acquired	1,943	5.7	341	general counsel
Apr 30, 2024	dolan christine	acquired	2,753	5.7	483	see remarks
Apr 30, 2024	burch andrew	acquired	9,798	5.7	1,719	see remarks
Apr 30, 2024	leddy peter michael	acquired	26,083	5.7	4,576	see remarks
Apr 30, 2024	herde kevin	acquired	10,146	5.7	1,780	chief financial officer
Apr 15, 2024	burch andrew	sold (taxes)	-135,907	8.11	-16,758	see remarks
Mar 15, 2024	herde kevin	sold (taxes)	-66,404	7.7	-8,624	chief financial officer
Mar 15, 2024	leddy peter michael	sold (taxes)	-51,697	7.7	-6,714	see remarks
Mar 15, 2024	oreshack kurt	sold (taxes)	-35,042	7.7	-4,551	general counsel
Mar 15, 2024	buzzeo rebecca	sold (taxes)	-33,618	7.7	-4,366	see remarks

Which funds bought or sold MRVI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Cipher Capital LP	sold off	-100	-91,713	-	-%
May 15, 2024	Lombard Odier Asset Management (Europe) Ltd	unchanged	-	106,000	433,500	0.03%
May 15, 2024	Centiva Capital, LP	added	2.01	62,670	241,616	0.01%
May 15, 2024	Bridgefront Capital, LLC	sold off	-100	-160,953	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	236	3,321,870	4,284,040	0.01%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-5.55	2,364,480	11,815,500	0.03%
May 15, 2024	VOLORIDGE INVESTMENT MANAGEMENT, LLC	sold off	-100	-2,570,820	-	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	added	50.96	21,375	42,787	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	42.00	173	-%
May 15, 2024	EVERGREEN CAPITAL MANAGEMENT LLC	added	22.28	41,605	108,861	-%

Are Funds Buying or Selling MRVI?

Are funds buying MRVI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRVI

No. of Funds

Unveiling Maravai LifeSciences Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 14, 2024	millennium management llc	5.4%	7,133,947	SC 13G
Feb 28, 2024	12 west capital management lp	8.8%	11,602,988	SC 13G/A
Feb 14, 2024	12 west capital management lp	8.78%	11,602,988	SC 13G
Feb 14, 2024	12 west capital management lp	8.78%	11,602,988	SC 13G
Feb 13, 2024	vanguard group inc	7.57%	10,003,894	SC 13G/A
Feb 08, 2024	maravai life sciences holdings 2, llc	8.63%	21,681,033	SC 13G/A
Jan 05, 2024	millennium management llc	4.5%	6,007,149	SC 13G/A
Nov 07, 2023	massachusetts financial services co /ma/	4.6%	6,058,247	SC 13G/A
Oct 26, 2023	millennium management llc	5.3%	6,975,927	SC 13G
Feb 14, 2023	select equity group, l.p.	1.9%	2,524,793	SC 13G/A

Recent SEC filings of Maravai LifeSciences Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	SC 13G	Major Ownership Report
May 09, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Maravai LifeSciences Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Maravai LifeSciences Holdings Inc News

Latest updates

Maravai LifeSciences Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-13.4%	64.00	74.00	67.00	69.00	79.00	205	191	243	244	228	205	218	148	98.00	88.00	47.00	51.00	-
Cost Of Revenue	9.2%	38.00	35.00	37.00	43.00	34.00	53.00	38.00	37.00	40.00	39.00	32.00	38.00	31.00	23.00	20.00	21.00	15.00	-
Costs and Expenses	2.2%	83.00	81.00	82.00	81.00	76.00	95.00	74.00	62.00	77.00	74.00	49.00	64.00	57.00	67.00	42.00	39.00	16.00	-
S&GA Expenses	6.3%	41.00	38.00	39.00	35.00	39.00	37.00	31.00	28.00	33.00	26.00	27.00	25.00	23.00	42.00	21.00	16.00	16.00	-
R&D Expenses	9.5%	5.00	5.00	4.00	4.00	4.00	5.00	5.00	4.00	4.00	9.00	2.00	2.00	2.00	2.00	2.00	2.00	4.00	-
EBITDA Margin	2.5%	2.40*	2.34*	0.26*	0.43*	0.58*	0.66*	0.69*	0.72*	0.72*	0.71*	0.66*	0.59*	0.47*	-	-	-	-	-
Interest Expenses	-29.5%	11.00	15.00	12.00	7.00	12.00	10.00	3.00	4.00	3.00	7.00	8.00	8.00	8.00	9.00	7.00	7.00	7.00	-
Income Taxes	-100.0%	0.00	766	-5.46	-1.42	-3.17	8.00	14.00	18.00	20.00	18.00	19.00	11.00	14.00	0.00	-0.36	-0.76	4.00	-
Earnings Before Taxes	-103.4%	-22.41	656	-20.56	-13.36	-4.52	96.00	114	175	167	145	151	146	89.00	15.00	39.00	1.00	28.00	-
EBT Margin	2.4%	2.19*	2.14*	0.14*	0.35*	0.53*	0.62*	0.66*	0.69*	0.68*	0.66*	0.60*	0.52*	0.38*	0.29*	-0.02*	-0.03*	-0.03*	-0.04*
Net Income	88.6%	-12.08	-105	-6.46	-6.54	-0.07	38.00	44.00	71.00	67.00	56.00	54.00	49.00	23.00	-	39.00	1.00	23.00	-
Net Income Margin	-16.1%	-0.48*	-0.41*	0.06*	0.14*	0.21*	0.25*	0.26*	0.27*	0.25*	0.23*	0.13*	0.16*	0.23*	0.31*	-0.02*	-0.02*	-0.03*	-0.03*
Free Cashflow	-56.9%	-14.13	-9.01	-1.66	-5.86	77.00	93.00	104	163	160	53.00	104	161	35.00	71.00	41.00	9.00	6.00	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-2.9%	1,445	1,487	2,268	2,264	2,315	2,282	2,249	2,172	2,043	1,918	1,895	1,601	1,352	1,271
Current Assets	-4.6%	668	700	701	699	766	848	836	759	619	740	687	644	426	332
Cash Equivalents	-2.3%	562	575	580	580	628	632	617	551	431	551	548	375	248	236
Inventory	-3.0%	50.00	51.00	49.00	47.00	55.00	43.00	62.00	60.00	51.00	52.00	56.00	48.00	47.00	33.00
Net PPE	-	-	-	-	-	-	53.00	48.00	47.00	48.00	46.00	108	105	105	101
Goodwill	0%	326	326	326	326	327	284	284	284	284	153	153	153	224	224
Liabilities	-4.3%	667	698	1,375	1,367	1,415	1,377	1,407	1,398	1,389	1,373	1,441	1,268	1,142	1,116
Current Liabilities	-32.5%	59.00	87.00	78.00	75.00	125	110	116	113	87.00	94.00	114	165	165	131
Long Term Debt	-0.2%	518	519	520	520	521	522	523	524	524	525	526	527	528	529
LT Debt, Current	0%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00
LT Debt, Non Current	-100.0%	-	519	520	520	521	522	523	524	524	525	526	527	528	529
Shareholder's Equity	86.5%	777	417	519	898	901	545	842	774	654	545	457	337	214	155
Retained Earnings	-4.2%	274	286	392	398	405	405	367	323	251	185	129	75.00	26.00	1.00
Additional Paid-In Capital	4.7%	134	129	125	120	114	138	134	131	129	128	173	118	86.00	85.00
Shares Outstanding	0.3%	132	132	132	132	132	132	132	132	131	115	109	104	97.00	-
Minority Interest	-1.7%	367	373	373	377	379	360	338	317	272	230	153	142	100	66.00
Float	-	-	-	-	1,370	-	-	-	3,121	-	-	-	3,745	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-208.7%	-8,467	7,790	14,166	19,194	85,074	99,335	110,059	164,279	162,304	58,743	105,562	165,939	38,326	79,431	51,428	11,615	9,713	-
Share Based Compensation	29.1%	12,057	9,342	9,987	9,272	5,987	5,995	4,740	4,308	3,627	2,230	3,567	2,383	2,278	21,696	1,849	576	508	-
Cashflow From Investing	67.1%	-4,244	-12,903	-15,520	-24,157	-69,730	-18,520	-5,847	-1,661	-241,584	-5,656	118,628	-4,533	-2,784	-8,849	-10,091	-3,059	28,067	-
Cashflow From Financing	-219.1%	-560	470	783	-43,134	-19,209	-66,123	-37,442	-43,411	-40,523	-49,580	-51,284	-34,127	-24,058	40,672	-943	-856	14,339	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,140	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MRVI Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 64,179	$ 79,025
Operating expenses:
Cost of revenue	38,335	33,676
Selling, general and administrative	40,885	38,671
Research and development	5,032	4,145
Restructuring	(1,212)	0
Total operating expenses	83,040	76,492
(Loss) income from operations	(18,861)	2,533
Other income (expense):
Interest expense	(10,864)	(11,833)
Interest income	7,210	6,045
Change in payable to related parties pursuant to the Tax Receivable Agreement	0	(1,436)
Other income	106	168
Loss before income taxes	(22,409)	(4,523)
Income tax expense (benefit)	271	(3,175)
Net loss	(22,680)	(1,348)
Net loss attributable to non-controlling interests	(10,602)	(1,281)
Net loss attributable to Maravai LifeSciences Holdings, Inc.	$ (12,078)	$ (67)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share)	$ (0.09)	$ (0.00)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share)	$ (0.09)	$ (0.00)
Weighted average number of Class A common shares outstanding, basic (in shares)	132,333	131,739
Weighted average number of Class A common shares outstanding, diluted (in shares)	132,333	131,739

MRVI Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 561,691	$ 574,962
Accounts receivable, net	36,685	54,605
Inventory	49,846	51,397
Prepaid expenses and other current assets	16,818	17,830
Government funding receivable	2,844	1,118
Total current assets	667,884	699,912
Property and equipment, net	161,628	162,900
Goodwill	326,029	326,029
Intangible assets, net	214,118	220,987
Other assets	74,982	77,622
Total assets	1,444,641	1,487,450
Current liabilities:
Accrued expenses and other current liabilities	35,405	60,237
Deferred revenue	2,210	3,360
Current portion of long-term debt	5,440	5,440
Current portion of finance lease liabilities	672	633
Total current liabilities	59,022	87,468
Long-term debt, less current portion	517,893	518,707
Finance lease liabilities, less current portion	31,714	31,897
Other long-term liabilities	58,623	59,494
Total liabilities	667,252	697,566
Commitments and contingencies (Note 6)
Stockholders’ equity:
Additional paid-in capital	134,482	128,503
Retained earnings	273,659	285,737
Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc.	410,659	416,753
Non-controlling interest	366,730	373,131
Total stockholders’ equity	777,389	789,884
Total liabilities and stockholders’ equity	1,444,641	1,487,450
Class A Common Stock
Stockholders’ equity:
Common stock	1,327	1,322
Class B Common Stock
Stockholders’ equity:
Common stock	1,191	1,191
Nonrelated Party
Current liabilities:
Accounts payable	8,226	10,729
Related Party
Current liabilities:
Accounts payable	$ 7,069	$ 7,069

About Maravai LifeSciences Holdings Inc

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

WEBSITE	maravai.com
INDUSTRY	Biotechnology
EMPLOYEES	660

Maravai LifeSciences Holdings Inc Frequently Asked Questions

What is the ticker symbol for Maravai LifeSciences Holdings Inc? What does MRVI stand for in stocks?

MRVI is the stock ticker symbol of Maravai LifeSciences Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Maravai LifeSciences Holdings Inc (MRVI)?

As of Thu May 16 2024, market cap of Maravai LifeSciences Holdings Inc is 1.47 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRVI stock?

You can check MRVI's fair value in chart for subscribers.

What is the fair value of MRVI stock?

You can check MRVI's fair value in chart for subscribers. The fair value of Maravai LifeSciences Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Maravai LifeSciences Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRVI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Maravai LifeSciences Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MRVI is over valued or under valued. Whether Maravai LifeSciences Holdings Inc is cheap or expensive depends on the assumptions which impact Maravai LifeSciences Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRVI.

What is Maravai LifeSciences Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, MRVI's PE ratio (Price to Earnings) is -11.21 and Price to Sales (PS) ratio is 5.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRVI PE ratio will change depending on the future growth rate expectations of investors.